Group 1: Market Performance - The Hong Kong stock market indices collectively rose, with the Hang Seng Index increasing by 1.63%, the Hang Seng China Enterprises Index rising by 1.74%, and the Hang Seng Tech Index up by 2.78% [1] - The film sector saw significant gains, with Alibaba Pictures rising by 11.58% and Maoyan Entertainment increasing by 4.42%, attributed to a recovery in the film market and expectations for a strong summer box office in 2024 [1] - Pharmaceutical stocks experienced widespread increases, with notable gains from companies like Four Seasons Medicine (up 14.56%) and King’s Ray Biotech (up 16.14%) [1] Group 2: Pharmaceutical Sector Developments - The pharmaceutical sector is benefiting from multiple positive factors, with 34 domestic innovative drugs approved for market by the end of May, nearing last year's total [2] - Chinese pharmaceutical companies showcased 71 original research results at ASCO, indicating a rapid advancement in innovation and research capabilities [2] Group 3: Technology and Other Sectors - Technology-related stocks, including short video and SaaS concepts, showed strong performance, with Kingdee International rising by 11.8% and Tencent Music increasing by 5.58% [2] - New consumption concepts and holiday-related stocks also performed well, with H&H International Holdings rising by 8.81% and Blucor soaring by 22.34% [3] Group 4: Declining Sectors - Gold and non-ferrous metal stocks experienced collective declines, with companies like Zhenfeng Gold dropping by 6.06% [3] - Other sectors such as beer, cosmetics, and tobacco also saw declines, with Budweiser Asia Pacific down by 2.06% [3][4]
【港股收评】三大股指集体走高！医药、科技股涨幅居前